Evidence map›Paper›PMID 34239995›Full record

ArticleJournal of clinical and translational research2021

Mutations of

Zhao Yang, Zongyi Shen, Di Jin, Nan Zhang, Yue Wang, Wanjun Lei, Zhiming Zhang, Haige Chen, Faiza Naz, Lida Xu and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of clinical and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Unraveling the dual role of METTL3-mediated mCancer biology & therapy · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.Journal of clinical and translational research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Zhao YangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Zongyi ShenCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Di JinDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Nan ZhangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Yue WangDepartment of Cancer Research, Novogene Bioinformatics Institute, Beijing 100016, China.
Wanjun LeiDepartment of Cancer Research, Novogene Bioinformatics Institute, Beijing 100016, China.
Zhiming ZhangDepartment of Cancer Research, Novogene Bioinformatics Institute, Beijing 100016, China.
Haige ChenDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.
Faiza NazCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Lida XuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Lei WangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Shihui WangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Xin SuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Changyuan YuCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Chong LiCore Facility for Protein Research, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Beijing University of Chemical Technology · CNInstitute of Biophysics · CNRenji Hospital · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimNeoadjuvant chemotherapy (NAC) followed by radical cystectomy is the current gold standard treatment for muscle-invasive urothelial bladder cancer (MIBC). Nonetheless, some MIBC patients showed limited pathological response after NAC. Herein, we used whole-exome sequencing (WES) to identify genetic mutations in MIBC that can predict NAC response.

methodsForty MIBC patients were enrolled in this study, in which 33 were successfully examined by WES and Sanger sequencing in the discovery cohort (

resultsIn the discovery cohort, the mutation frequencies of

conclusionThe somatic mutation of RELEVANCE FOR PATIENTS: MIBC patients bearing mutated

Indexed as

biomarkerMETTL3muscle-invasive bladder cancerneoadjuvant chemotherapypathological response

Identifiers

PMID34239995
PMCPMC8259609
OpenAlexW3181017530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.